Skip to content

Clinical evaluation of the Articulinx device for the carpometacarpal joint.

Clinical evaluation of the Articulinx device for the carpometacarpal joint. - Articulinx CMC study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON38020
Enrollment
30
Registered
2011-04-18
Start date
2011-04-27
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rizarthrosis thumb arthritis

Interventions

Sponsors

Articulinx Inc.
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adults 35 -75 years old with osteoarthritis of the carpometacarpal (CMC-I) joint. VAS- painscore > 40 at baseline. Subluxation less than 1/3. Patients capable of providing informed consent.

Exclusion criteria

Exclusion criteria: Significant and affecting pathology of the radial side of the hand and wrist. Significant osteophytes (> 2 mm) and free floating bodies in CMC-I joint Rheumatoid and/or Metabolic disorders of the bone. Prior surgery. Participating in another study. Pregnancy and lactation.

Design outcomes

Primary

MeasureTime frame
Incidence of device- and procedure-related adverse events intra-operatively, and through two years follow-up. Average CMC-I joint pain score post-procedure compared to pre-operative baseline through two years follow-up.

Secondary

MeasureTime frame
Change in pain medication use for CMC-I joint as compared to baseline. Change in CMC-I joint function post-procedure as compared to baseline. Change in DASH scores as compared to baseline

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)